The role of moxonidine, a second generation centrally acting antihypertensive agent as antihypertensive therapy in the obese.
作者信息
Karlafti E, Hatzitolios A, Savopoulos Ch
机构信息
1st Medical Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
出版信息
Hippokratia. 2014 Apr;18(2):189.
Abstract
摘要
相似文献
1
The role of moxonidine, a second generation centrally acting antihypertensive agent as antihypertensive therapy in the obese.
Hippokratia. 2014 Apr;18(2):189.
2
Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
J Pharmacol Exp Ther. 1993 Jan;264(1):172-82.
3
Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
J Hum Hypertens. 1997 Aug;11 Suppl 1:S29-45.
4
Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection.
J Pharm Bioallied Sci. 2013 Oct;5(4):253-6. doi: 10.4103/0975-7406.120067.
5
Moxonidine: pharmacology, clinical pharmacology and clinical profile.
Blood Press Suppl. 1998;3:23-7. doi: 10.1080/080370598438447-1.
6
Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats.
J Hypertens. 2016 May;34(5):993-1004. doi: 10.1097/HJH.0000000000000887.
7
[Pharma-clinics. Medication of the month. Moxonidine (Moxon)].
Rev Med Liege. 2000 Jan;55(1):61-3.
8
Moxonidine: a new antiadrenergic antihypertensive agent.
J Hypertens Suppl. 1999 Aug;17(3):S41-54.
9
Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
J Cardiovasc Pharmacol. 1996;27 Suppl 3:S26-37. doi: 10.1097/00005344-199627003-00005.
10
The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
J Hypertens Suppl. 1997 Jan;15(1):S9-23. doi: 10.1097/00004872-199715011-00002.
本文引用的文献
1
Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection.
J Pharm Bioallied Sci. 2013 Oct;5(4):253-6. doi: 10.4103/0975-7406.120067.
2
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
3
Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate.
Clin Auton Res. 2001 Apr;11(2):99-108. doi: 10.1007/BF02322053.
Zotero 插件